Table 3 Overall and stratified risk estimates of IL-6 gene -174G/C variant for cancer risk under three genetic models.
From: Circulating interleukin-6 and cancer: A meta-analysis using Mendelian randomization
Groups | Studies | Allelic model | Genotypic model | Dominant model | |||
|---|---|---|---|---|---|---|---|
OR; 95% CI; P | I 2 | OR; 95% CI; P | I 2 | OR; 95% CI; P | I 2 | ||
Overall | 87 | 1.02; 0.98–1.07; 0.290 | 66.6% | 1.07; 0.99–1.16; 0.103 | 54.0% | 1.02; 0.97–1.08; 0.465 | 65.1% |
Ethnicity | |||||||
Caucasian | 46 | 1.05; 0.98–1.12; 0.138 | 72.2% | 1.09; 0.97–1.23; 0.136 | 59.5% | 1.07; 0.98–1.17; 0.155 | 71.4% |
Asian | 9 | 1.03; 0.75–1.42; 0.870 | 68.8% | 1.95; 1.19–3.20; 0.009 | 17.9% | 0.90; 0.66–1.22; 0.483 | 52.7% |
Mixed | 31 | 0.98; 0.93–1.03; 0.374 | 50.6% | 0.97; 0.88–1.06; 0.450 | 27.5% | 0.97; 0.91–1.04; 0.430 | 53.0% |
Sample size | |||||||
<500 | 54 | 1.03; 0.92–1.15; 0.615 | 73.7% | 1.17; 0.94–1.45; 0.163 | 61.8% | 1.03; 0.89–1.20; 0.654 | 72.7% |
>=500 | 33 | 1.01; 0.98–1.04; 0.730 | 43.5% | 1.02; 0.96–1.08; 0.615 | 29.2% | 1.01; 0.96–1.05; 0.817 | 41.4% |
Cancer type | |||||||
Myeloma | 6 | 1.06; 0.89–1.28; 0.496 | 0.0% | 1.13; 0.72–2.50; 0.592 | 0.0% | 1.09; 0.84–1.40; 0.521 | 0.0% |
Gastric | 8 | 1.01; 0.79–1.28; 0.960 | 68.5% | 1.12; 0.81–1.54; 0.498 | 28.2% | 1.04; 0.72–1.51; 0.819 | 74.1% |
Colorectal | 16 | 1.00; 0.93–1.07; 0.941 | 63.3% | 0.99; 0.88–1.13; 0.914 | 51.7% | 1.01; 0.92–1.11; 0.850 | 58.1% |
Lung | 5 | 1.03; 0.95–1.11; 0.530 | 3.6% | 1.06; 0.91–1.22; 0.463 | 0.0% | 1.03; 0.86–1.25; 0.743 | 41.8% |
Breast | 14 | 0.99; 0.93–1.05; 0.716 | 44.0% | 1.02; 0.89–1.16; 0.824 | 11.3% | 0.99; 0.89–1.09; 0.773 | 58.2% |
Lymphoma | 4 | 1.00; 0.95–1.07; 0.888 | 0.0% | 1.01; 0.89–1.15; 0.855 | 0.0% | 1.00; 0.92–1.10; 0.940 | 0.0% |
Liver | 5 | 0.74; 0.61–0.89; 0.001 | 0.0% | 0.59; 0.36–0.95; 0.029 | 0.0% | 0.67; 0.52–0.88; 0.004 | 21.5% |
Prostate | 7 | 0.95; 0.80–1.14; 0.597 | 79.4% | 0.94; 0.66–1.34; 0.724 | 76.3% | 0.96; 0.81–1.13; 0.609 | 58.8% |
Oral | 3 | 1.49; 0.58–3.81; 0.409 | 95.0% | 2.38; 0.34–16.93; 0.385 | 91.6% | 1.98; 0.54–7.26; 0.303 | 95.4% |
Matched | |||||||
NA | 23 | 1.00; 0.94–1.06; 0.961 | 43.1% | 0.99; 0.89–1.10; 0.821 | 18.1% | 1.00; 0.92–1.08; 0.926 | 41.1% |
YES | 60 | 1.03; 0.98–1.09; 0.235 | 71.5% | 1.11; 1.00–1.23; 0.044 | 59.9% | 1.03; 0.96–1.11; 0.389 | 70.8% |
NO | 4 | 0.99; 0.68–1.45; 0.976 | 70.4% | 1.00; 0.40–2.50; 0.999 | 75.0% | 0.97; 0.69–1.36; 0.846 | 35.1% |
Control source | |||||||
Population | 57 | 1.01; 0.97–1.06; 0.592 | 61.5% | 1.02; 0.94–1.11; 0.622 | 47.9% | 1.02; 0.96–1.08; 0.569 | 63.4% |
Hospital | 30 | 1.02; 0.91–1.14; 0.701 | 73.3% | 1.17; 0.96–1.43;.0118 | 58.9% | 1.00; 0.86–1.16; 0.973 | 68.7% |
Study design | |||||||
Retrospective | 59 | 1.02; 0.96–1.08; 0.546 | 69.0% | 1.09; 0.97–1.23; 0.163 | 54.1% | 1.01; 0.93–1.10; 0.751 | 68.8% |
Prospective | 28 | 1.03; 0.97–1.09; 0.316 | 61.6% | 1.06; 0.95–1.19; 0.328 | 55.7% | 1.04; 0.96–1.11; 0.350 | 54.8% |
